Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-09-30Clinical Trial Update: Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH) [Phase 2]
Phase 2 dose-response study evaluating safety and efficacy of beraprost sodium modified release in pulmonary arterial hypertension has compl…
-
CLINICAL_TRIALS trial_result · 2020-09-24Clinical Trial Update: REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension [Phase 4]
A Phase 4 trial investigating right ventricular remodeling in pulmonary arterial hypertension has completed, with results posted.
-
FDA approval · 2020-09-15FDA Approved: ADCIRCA — Supplemental Application (United Therapeutics Corporation)
FDA approves a supplemental application for ADCIRCA (tadalafil) from United Therapeutics Corporation. The approval indicates the submitted s…
-
CLINICAL_TRIALS trial_result · 2020-09-11Clinical Trial Update: The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension [Phase 3]
Phase 3 trial evaluating initial triple oral therapy versus initial dual therapy in newly diagnosed pulmonary arterial hypertension; results…
-
CLINICAL_TRIALS trial_result · 2020-09-09Clinical Trial Update: Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension [Phase 2]
Phase 2 trial update on treprostinil for patients with pulmonary arterial hypertension associated with interstitial lung disease, including …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-09-07Clinical Trial Update: A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension [Phase 3]
A Phase 3 trial of BPS-314d-MR-PAH-303 in pulmonary arterial hypertension was terminated; results were posted after completion.
-
CLINICAL_TRIALS research · 2020-08-27Clinical Trial Update: Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension [Phase 1, Phase 2]
Pilot study evaluating safety and efficacy of sulfasalazine in pulmonary arterial hypertension across Phase 1 and Phase 2.
-
FDA approval · 2020-08-19FDA Tentative Approval: REMODULIN — Supplemental Application (United Therapeutics Corporation)
FDA has issued tentative approval for a United Therapeutics supplemental submission for REMODULIN (treprostinil).
-
FDA approval · 2020-07-15FDA Approved: SILDENAFIL — Supplemental Application (Amneal Pharmaceuticals NY LLC)
The FDA approved Amneal Pharmaceuticals NY LLC's supplemental application for sildenafil (generic sildenafil), authorizing the continued com…
-
CLINICAL_TRIALS trial_result · 2020-07-14Clinical Trial Update: Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension [Phase 2]
Phase 2 trial reporting safety and efficacy data for APD811 in pulmonary arterial hypertension has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-06-16Clinical Trial Update: Beta-blockers in Pulmonary Arterial Hypertension [Phase 2]
Phase 2 trial assessing beta-blockers in pulmonary arterial hypertension was terminated; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-06-09Clinical Trial Update: A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients [Phase 2]
Phase 2 open-label, dose-finding study evaluating safety and tolerability of beraprost sodium modified release in pulmonary arterial hyperte…
-
FDA approval · 2020-05-22FDA Approved: STERILE DILUENT FOR TREPROSTINIL — Original Application (Dr.Reddy's Laboratories Inc.,)
FDA approved the Original Application for a sterile diluent (water) intended for use with treprostinil, manufactured by Dr. Reddy's Laborato…
-
CLINICAL_TRIALS trial_result · 2020-04-30Clinical Trial Update: Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH) [Phase 2]
Phase 2 trial update on early treatment of borderline pulmonary arterial hypertension associated with systemic sclerosis (SSc-APAH); study c…
-
CLINICAL_TRIALS trial_result · 2020-04-21Clinical Trial Update: A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH) [Phase 2]
Phase 2 dose-escalation trial in pulmonary arterial hypertension (PAH) completed; results posted in 2020.
-
FDA approval · 2020-04-20FDA Approved: AMBRISENTAN — Supplemental Application (Cipla USA Inc.)
The FDA approved Cipla USA Inc.'s supplemental application for Ambrisentan.
-
FDA approval · 2020-04-20FDA Approved: AMBRISENTAN — Supplemental Application (Zydus Lifesciences Limited)
FDA approves a supplemental application for AMBRISENTAN by Zydus Lifesciences Limited, resulting in approval of a generic ambrisentan produc…
-
FDA approval · 2020-04-08FDA Approved: OPSUMIT — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved a supplemental application for OPSUMIT (macitentan) by Actelion Pharmaceuticals US, Inc., updating the product labeling via…
-
CLINICAL_TRIALS trial_result · 2020-03-23Clinical Trial Update: A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH) [Phase 3]
Phase 3 trial update for tadalafil in pediatric pulmonary arterial hypertension has completed with results posted.
-
CLINICAL_TRIALS withdrawal · 2020-03-03Clinical Trial Update: Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain [Phase 4]
Phase 4 trial investigating hypotonic treprostinil subcutaneous infusion for control of site pain related to treprostinil; the study has bee…
-
FDA approval · 2020-03-02FDA Approved: SILDENAFIL — Original Application (Exelan Pharmaceuticals, Inc.)
FDA approves an Original Application (ANDA) for sildenafil by Exelan Pharmaceuticals, enabling a generic version of the erectile dysfunction…
-
CLINICAL_TRIALS trial_result · 2020-02-28Clinical Trial Update: Beraprost-314d Added-on to Tyvaso® (BEAT) [Phase 3]
Phase 3 trial BEAT evaluating adding beraprost to Tyvaso in pulmonary arterial hypertension has completed with results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-02-28Clinical Trial Update: Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients [Phase 2]
Long-term extension study of QCC374 in pulmonary arterial hypertension (Phase 2) was terminated; results posted in 2020.
-
FDA approval · 2020-02-21FDA Approved: REVATIO — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for REVATIO (sildenafil citrate) filed by Viatris Specialty LLC. The action typically updates or exp…
-
FDA approval · 2020-02-21FDA Approved: SILDENAFIL — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for sildenafil from Aurobindo Pharma Limited.